Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
Status:
Terminated
Trial end date:
2013-11-18
Target enrollment:
Participant gender:
Summary
This study is designed to compare safety and efficacy of monotherapy finasteride to
combination therapy (finasteride and tamsulosin) in Asian men with benign prostatic
hyperplasia (BPH) who are at least 50 years of age or older. The primary hypotheses are that
concomitantly-dosed finasteride 5 mg and tamsulosin 0.2 mg will be superior with respect to
BPH symptoms compared to monotherapy with finasteride 5 mg as measured by change from
baseline on the International Prostate Symptoms Score (IPSS) and will be superior with
respect to prostate volume reduction compared to montherapy with tamsulosin 0.2 mg as
measured by percent change from baseline in prostate volume.